Figure 6
From: Inhibition of Bcl-2/Bcl-xL and c-MET causes synthetic lethality in model systems of glioblastoma
Dual inhibition of c-MET and Bcl-2/Bcl-xL leads to enhanced tumor growth suppression in a PDX model of GBM. (A) GBM12 PDX cells were implanted into the subcutis of immunocompromised Nu/Nu mice. After tumors were established (palpable), randomization was performed to assign four distinct treatment groups. These groups are designated as: Control; ABT263 (ABT) (75 mg/kg); Crizotinib (Crizo) (50 mg/kg) and ABT263 + Crizotinib (ABT + Crizo). Shown are tumor volumes over time. Values are means and SD. n = 9 in each group. (B) The indicated groups were assessed for body weight. Shown are means and SD. (C) Shown is the last measurement as a dot-plot (means and SD) with corresponding statistical analysis. n = 9. (D) Gross images of representative tumors from each individual group at day 16. (E) Tumors were resected and fixed in formalin according to standard operating procedure. Thereafter, they were embedded in paraffin, cut and stained with conventional H.E. staining. A scale bar accompanies each image (200 μm). Ctrl: Vehicle, ABT: ABT263. Crizo: Crizotinib, ABT + Crizo: ABT263 + Crizotinib. (F) The tumors were stained with TUNEL and photographs were taken. Scale bar indicates 50 μm.
